title: Suboptimal treatment of risk factor for atherosclerosis in critical limb ischemia.
abstract: OBJECTIVE
  The epidemiology of critical limb ischemia (CLI) is insufficiently studied, and treatment of risk factors for atherosclerosis has received less attention in CLI patients than in patients with coronary or precerebral atherosclerosis. The aim of this study was to establish the incidence of CLI and the quality of risk factor treatment in Swedish CLI patients.
  
  
  METHODS
  During 14 months, 316 consecutive CLI patients were referred to the Malmo Department of Vascular Diseases. Two hundred and fifty-nine (82%) consented to evaluation of intercurrent disease, medication, ankle and arm blood pressures (BP), plasma glucose and lipid levels, p-homocysteine, cardiolipin antibodies and activated protein C (APC)-resistance.
  
  
  RESULTS
  The incidence of CLI was 38/100,000 inhabitants/year. Patient age was 75 +/- 10 years, and BP 147 +/- 26/75 +/- 14 mmHg. Systolic or diastolic BP above recommended levels (140/90 mmHg) occurred in 137 (53%) patients. P-cholesterol was 4.8+/-1.2 mMol/L, but cholesterol above recommended level (5 mMol/L) or LDL above recommended level (3 mMol/L) occurred in 125 (48%) patients. Only 24% of patients met national recommendations for both BP and lipid levels. Diabetes mellitus was previously known in 123 (47%) patients, and another 12 (5%) patients showed diabetic fasting glucose levels during the hospital stay. Eighty-four (32%) patients were active, and 72 (28%) were former smokers. Myocardial infarction or angina pectoris had previously been diagnosed in 123 (47%) patients. P-homocysteine was 17 +/- 7 _mol/l, cardiolipin antibodies occurred in 71 (27%) and APC-resistance in 34 (13%) patients.
  
  
  CONCLUSIONS
  Patients with CLI show high comorbidity in vascular diseases and high prevalence of modifiable risk factors for atherosclerotic vascular disease. The use of evidence-based medical therapy is suboptimal in this high-risk group.
authors.affiliation: Department of Vascular Diseases, University of Lund, Malmö University Hospital, Malmö, Sweden. jamal.barani@skane.se
authors.forename: J
authors.initials: J
authors.lastname: Barani
authors.forename: I
authors.initials: I
authors.lastname: Mattiasson
authors.forename: B
authors.initials: B
authors.lastname: Lindblad
authors.forename: A
authors.initials: A
authors.lastname: Gottsäter
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000787:Angina Pectoris / Q000453:epidemiology; D017153:Antibodies, Anticardiolipin / Q000032:analysis; D050197:Atherosclerosis / Q000453:epidemiology*; D015897:Comorbidity; D005260:Female; D006801:Humans; D007511:Ischemia / Q000453:epidemiology*; D007866:Leg / Q000098:blood supply*; D008297:Male; D009203:Myocardial Infarction / Q000453:epidemiology; D012307:Risk Factors
chemical_list: D017153:Antibodies, Anticardiolipin